

CONFIDENTIAL CASE STUDY

PANCREASaver® · HEALTH SCREENING

How a High-End Health Screening Center Built a Scalable AI-Enabled Pancreatic Cancer Screening Program

A high-end health screening center in Taiwan integrated PANCREASaver® into its contrast-enhanced abdominal CT workflow—creating a differentiated premium screening program with measurable patient adoption and incremental revenue.

25/day

Current average
PANCREASaver®
cases

650/month

Current average
monthly cases

2023

TFDA
license
issued

Making better use of the abdominal CT pathway

Taiwan's National Health Insurance system provides a large population-based healthcare environment in which medical imaging is widely used. That creates both a clinical opportunity and an operational challenge: how can existing abdominal CT examinations deliver more actionable value?

2.59M

Total CT examinations in Taiwan in 2022, based on an analysis of National Health Insurance claims data.^[1]

~900K

Estimated annual abdominal CT examinations, based on the center team's internal claims-data analysis.^[2]

2,659

Pancreatic cancer deaths reported in Taiwan in 2021 by the Taiwan Cancer Registry.^[3]

Pancreatic cancer remains a high-mortality disease in Taiwan

The Taiwan Cancer Registry reported a crude pancreatic cancer mortality rate of **11.38 per 100,000** people and an age-adjusted mortality rate of **5.94 per 100,000** in 2021. Pancreatic cancer ranked seventh among cancer mortality causes in the published table.^[3]

A rising disease burden

A nationwide study of Taiwan's cancer registry and cause-of-death data found that age-standardized pancreatic cancer incidence increased from 3.7 per 100,000 in 1999 to 5.0 per 100,000 in 2012. Mortality increased from 3.5 to 4.1 per 100,000 during the same period.^[4]

Why CT workflow matters

The opportunity is not necessarily to add another examination. It is to provide an additional AI-assisted review layer for imaging that is already part of a patient's health examination.

Creating a differentiated screening experience without disrupting workflow

The center wanted to offer

- Advanced imaging and AI-assisted analysis
- More personalized health information
- Earlier awareness of potential pancreatic findings
- A premium service with clear patient value
- No additional CT appointment
- No replacement of radiologist review

The implementation principle

Use the existing contrast-enhanced abdominal CT pathway, then add an AI-assisted second-read layer for qualified clinical review.

The same abdominal CT examination, supported by an additional layer of AI-assisted review.

The patient pathway

01	02	03	04	05
Health examination	Contrast-enhanced CT	AI analysis	Radiologist review	Follow-up discussion
Patient selects the AI-enabled examination package.	Existing abdominal CT examination is performed.	PANCREASaver [®] analyzes the CT images automatically.	Suspicious findings are reviewed and confirmed by a qualified professional.	Findings are incorporated into the examination communication.

The clinical role of PANCREASaver[®]

PANCREASaver[®] is an AI-assisted computer-aided detection tool for contrast-enhanced abdominal CT. It supports radiologist review; it does not replace radiologist judgment or independently establish a diagnosis.

From a five-patient pilot to approximately 25 cases per day

A measured rollout

Month one · 5 patients

Focused pilot to validate patient interest, staff communication, image review and report integration.

Month two · 10 patients

Utilization doubled as the center refined how it presented the AI-enabled examination.

Current · ~25 cases per day

The program now averages approximately 25 PANCREASaver[®] cases per day, or about 650 cases per month.

Current utilization

25

Approximately 25 PANCREASaver[®] cases per day

Current average daily utilization

650

Approximately 650 cases per month

Approximately 25 PANCREASaver[®] cases per day

Incremental package value

US\$631

Approximate incremental revenue per patient
NT\$20,000 / patient

US\$410K

Estimated monthly incremental revenue
650 cases × US\$631


US\$985K

Approximate total monthly center revenue
Broader center operation, inclusive of AI-enabled offerings

How AI created additional marginal value

The center used PANCREASaver[®] to create an AI-enabled premium examination option around existing CT imaging. The resulting value came from a combination of patient adoption, differentiated service design and incremental package revenue—not from attributing the center's total revenue to PANCREASaver[®] alone.

A clinical proposition supported by published evidence



Illustrative view of the same CT examination with PANCREASaver[®] output. AI findings require qualified clinical review.

Published performance

92.1%

Sensitivity for tumors under 2 cm in the cited *The Lancet Digital Health* study setting.^[8]

AUC 0.95

Nationwide real-world validation across 1,473 CT studies in *Radiology*.^[7]

Taiwan regulatory status



TFDA License No.

衛部醫器製字第

007946號

Issued in 2023;
publicly listed as
valid through July
13, 2028.^[9]

U.S. status

FDA Breakthrough Device Designation

510(k) submitted July 2026 and under FDA review. PANCREASaver[®] is not yet cleared for U.S. marketing.

“This deep learning–based tool had very good accuracy, and sensitivity approaching that of subspecialist radiologists... Tools such as this promise to benefit routine workflow and patient care.”

— Aisen & Rodrigues, *Radiology* editorial, 2023

A repeatable model for AI-enabled health screening

The result

The center created a scalable AI-enabled health screening program by combining an existing CT pathway with AI-assisted pancreatic cancer detection.

- Progressive patient adoption
- Distinctive premium screening proposition
- Approximately 650 monthly cases
- Estimated US\$410K monthly incremental package revenue

The playbook

1

Start with a focused pilot.

2

Integrate AI into the existing CT workflow.

3

Refine staff and patient communication.

4

Measure adoption and scale with demand.

Conclusion

This case shows how a high-end health screening center can use AI not only to support imaging review, but also to create a differentiated service model around examinations already being performed.

References

- [1] Taiwan National Health Insurance CT utilization analysis, reported by UDN Health: <https://health.udn.com/health/story/5959/7331843>
- [2] Internal analysis of Taiwan National Health Insurance claims data. The abdominal CT estimate requires publication of the claims period, procedure-code definition and calculation method.
- [3] Taiwan Cancer Registry. *Incidence and mortality rates for the top 10 cancer in Taiwan, 2021*. Official PDF
- [4] Tseng CM et al. *Incidence and mortality of pancreatic cancer on a rapid rise in Taiwan, 1999–2012*. Cancer Epidemiology. 2017;49:75–84. DOI
- [5] Chang JS et al. *The incidence and survival of pancreatic cancer by histology... from Taiwan*. Cancer Medicine. 2018;7:5775–5788. PMC
- [6] Su YY et al. *Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation*. Biomedical Journal. 2024;47(3):100696. DOI
- [7] Chen PT et al. *Pancreatic Cancer Detection on CT Scans with Deep Learning*. Radiology. 2023. PMID 36098642
- [8] Liu KL et al. *Deep learning to distinguish pancreatic cancer tissue...* The Lancet Digital Health. 2020. PMID 33328124
- [9] Taiwan FDA AI/ML medical-device listing and public license record: [TFDA listing · license record](#)

Disclaimer: This case study is anonymized at the customer's request. Patient volumes and financial figures are based on information provided by the participating center. PANCREASaver[®] is an AI-assisted decision-support tool for qualified healthcare professionals and does not replace radiologist judgment or independently establish a diagnosis. Currency conversions are approximate. Regulatory status and availability vary by country.